Abstract
Correlation of the heterogeneic immunopathological profiles of multiple sclerosis (MS) lesions with the paraclinical and clinical markers of disease may be important in the development of therapeutic approaches in MS. This and other issues were discussed at a recent meeting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
